# Lantheus completes merger with Progenics Pharmaceuticals

Lantheus Holdings completed its merger with Progenics Pharmaceuticals, an oncology company. Progenics stockholders received 0.31 shares of Lantheus common stock and a contingent value right per share.

- Type: Acquisition
- Announced: 2020-06-22
- Where: United States
- Status: completed
- Products: diagnostic imaging agents, oncology therapeutics
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Lantheus Holdings](https://endata.com/companies/23794.md) (acquirer)
- [Progenics Pharmaceuticals](https://endata.com/companies/48033.md) (target)

## Sources

- [lantheusholdings.gcs-web.com](https://lantheusholdings.gcs-web.com/news-releases/news-release-details/lantheus-completes-merger-progenics), 2020-06-22: "This combination forms an innovative company with a diversified diagnostics and therapeutics portfolio."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.